Topical Ruxolitinib Evaluation in Chronic Hand Eczema

NCT05906628 PHASE2 COMPLETED Results posted

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adult participants with diagnosis of chronic hand eczema (CHE) and moderate to severe disease activity (Investigator's Global Assessement (IGA) of CHE score 3 or 4).

Details

Lead sponsor	Incyte Corporation
Phase	PHASE2
Status	COMPLETED
Enrolment	186
Start date	Mon Jul 31 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Dec 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Hand Eczema

Interventions

• Ruxolitinib cream
• Vehicle

Countries

Canada, United States, Germany, Poland